Article Sidebar
Published:
Oct 8, 2023DOI:
10.4314/tjpr.v22i9.7Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Investigation of the mechanism of <i>Astragalus membranaceus</i> in the treatment of lumbar disc herniation using network pharmacology
Abstract
Purpose: To determine the underlying mechanisms of action of Astragalus membranaceus in lumbar disc herniation (LDH) treatment.
Methods: This study utilized network pharmacology analysis and STRING database to identify compound targets and visualize PPI network. Furthermore, an LDH model was induced in human nucleus pulposus cells using lipopolysaccharide (LPS), and then the vital target genes were evaluated in this model treated with active components of Astragalus membranaceus.
Results: Network pharmacology analysis indicates that several key proteins, including vascular endothelial growth factor A (VEGF A), AKT1, JUN, prostaglandin-endoperoxide synthase 2 (PTGS2), interleukin-6 (IL-6), matrix metallopeptidase 9 (MMP9), interleukin-1β (IL-1β), C-X-C motif chemokine ligand 8 (CXCL8), epidermal growth factor (EGF) and matrix metallopeptidase 2 (MMP2) may play essential roles in LDH treated with Astragalus membranaceus. The active components in Astragalus membranaceus suppressed the production of IL-1β and IL-6, and increased the expressions of VEGF A, MMP9 and MMP2 in LPS-induced LDH model.
Conclusion: The active components of Astragalus membranaceus effectively inhibits inflammation in LPS-induced LDH model, indicating that Astragalus membranaceus is a potential therapeutic candidate for LDH treatment.
